Third Bridge News Today

Even if you don’t believe in the paranormal, a bridge in Colorado has such a troubling track record of tragedy and ghost stories that most opt to steer clear of it.

Zscaler posts strong growth, but SentinelOne shares fall on missed outlook metric - SiliconANGLE

Xpeng narrowed its losses last quarter as deliveries and vehicle margins improved. Technology licensing fees from Volkswagen also helped.

Experts see discounts for Xpengs G6 and G9 electric SUVs boosting deliveries volume in the near term, but warn that new entrants such as Xiaomi will pressure Xpengs sales in the long run.

Xpeng Motors is trading sharply higher in early US price action today after the company reported an impressive set of numbers for Q1

In recent quarters, Cisco has benefited from an increase in spending, with companies trying to boost their growing artificial intelligence and cloud computing needs.

Cisco revealed its financial result, saying its revenue fell 13 percent to $12.7 billion with net income of $1.9 billion for third quarter

Explained: Why Tesla CEO Elon Musk wants to buy Twitter and all other details - Rashtra News : Rashtra News #Explained #Tesla #CEO #Elon #Musk #buy #Twitter #details #Times #India Tesla CEO Elon Musk now says he wants to buy Twitter outright, taking it private to restore its commitment to what he terms "free speech."

Amgen investors eyeing dramatic share price gains for rivals with successful obesity drugs will be focused on any updates the biotech company may provide on its own weight-loss drug candidates when it reports quarterly earnings on Thursday. Amgen has said it expects to have first-in-human results from a small, early-stage trial of experimental oral compound AMG786 before the end of June. "We are still collecting and analyzing the data," Amgen Chief Scientific Officer Jay Bradner told...

By Deena Beasley (Reuters) - Amgen investors eyeing dramatic share price gains for rivals with successful obesity drugs will be focused on any updates the biotech company may provide on its own weight-loss drug candidates when it reports quarterly ...